Sofinnova Partners, a Life Sciences venture capital firm focused on Europe, has appointed Maina Bhaman as Partner.
Maina Bhaman comes to Sofinnova Partners with a long track record as a healthcare investor.
Prior to joining, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK) since 2006. Bhaman has led or co-led numerous investments and sat on the Board of a number of UK biotech companies, such as Autifony, Cellmedica, Psioxus Therapeutics, Pulmocide, Topivert Pharma, Puridify (sold to GE), Thiakis (sold to Wyeth) and Respivert (sold to J&J).
Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine. Bhaman has a BSc from the University of Texas at Austin (United States) and an MBA from the Imperial Business School in London (United Kingdom).
Commenting on the announcement, she said:
“I am thrilled to join such an experienced team as Sofinnova Partners. We have worked together on a number of co-investments, and clearly share a common approach and vision. I am looking forward to continue to pursue my passion of backing entrepreneurs developing paradigm-shifting technologies that may significantly improve patients’ life”.